Home  |  Contact

UniProtKB/Swiss-Prot O43318: Variant p.Gly168Arg

Mitogen-activated protein kinase kinase kinase 7
Gene: MAP3K7
Chromosomal location: 6q16.1-q16.3
Variant information

Variant position:  168
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Glycine (G) to Arginine (R) at position 168 (G168R, p.Gly168Arg).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from glycine (G) to large size and basic (R)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Frontometaphyseal dysplasia 2 (FMD2) [MIM:617137]: A form of frontometaphyseal dysplasia, a progressive sclerosing skeletal dysplasia affecting the long bones and skull. Characteristic features include supraorbital hyperostosis, cranial hyperostosis, undermodeling of the small bones, flared metaphyses, and digital anomalies. Extra-skeletal manifestations include hearing loss, cardiac malformations, and stenosis, particularly of the upper airway and urinary tract. FMD2 inheritance is autosomal dominant. {ECO:0000269|PubMed:27426733}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In FMD2; increases autophosphorylation; no effect on MAPK signaling; no effect on NF-kappa-B signaling.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.

Sequence information

Variant position:  168
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  606
The length of the canonical sequence.

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

Chain 1 – 606 Mitogen-activated protein kinase kinase kinase 7
Domain 36 – 291 Protein kinase
Region 1 – 300 Interaction with MAPK8IP1
Active site 156 – 156 Proton acceptor
Modified residue 184 – 184 Phosphothreonine; by autocatalysis
Modified residue 187 – 187 Phosphothreonine; by autocatalysis
Cross 158 – 158 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)
Mutagenesis 158 – 158 K -> R. Abolishes ubiquitination.
Turn 166 – 169

Literature citations

Mutations in MAP3K7 that alter the activity of the TAK1 signaling complex cause frontometaphyseal dysplasia.
Wade E.M.; Daniel P.B.; Jenkins Z.A.; McInerney-Leo A.; Leo P.; Morgan T.; Addor M.C.; Ades L.C.; Bertola D.; Bohring A.; Carter E.; Cho T.J.; Duba H.C.; Fletcher E.; Kim C.A.; Krakow D.; Morava E.; Neuhann T.; Superti-Furga A.; Veenstra-Knol I.; Wieczorek D.; Wilson L.C.; Hennekam R.C.; Sutherland-Smith A.J.; Strom T.M.; Wilkie A.O.; Brown M.A.; Duncan E.L.; Markie D.M.; Robertson S.P.;
Am. J. Hum. Genet. 99:392-406(2016)

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.